ABSTRACT
We report on the design, construction, and performance of a custom apparatus built to measure the frequency- and temperature-dependent absorptivity of millimeter-wave light by cosmic analog dusts. We highlight the unique challenges faced as well as a few key innovations that are part of the instrument. Among those is an ultra-compact Fourier transform spectrometer. We have measured its effective frequency range and FWHM resolution to be 150-2100 GHz and â¼45GHz, respectively. Another innovation is a cold sample positioner whose temperature can be controlled within the range of 3.7-50 K. The use of a pulse-tube cryocooler results in a pulse-synchronous signal that dominates the detector (bolometer) signal. Methods used to address that challenge are also presented.
ABSTRACT
Lipoedema is painful nodular subcutaneous adipose tissue (SAT) on legs and arms of women sparing the trunk. People with Dercum disease (DD) have painful SAT masses. Lipoedema and DD fat resists loss by diet and exercise. Treatments other than surgery are needed. Six women with lipoedema and one with DD underwent twelve 90-min sessions over 4 weeks. Body composition by dual X-ray absorptiometry scan, leg volume, weight, pain, bioimpedance, tissue size by caliper and ultrasound were analysed before and after SAT therapy by paired t-tests. There was a significant decrease from baseline to end of treatment in weight, 87.6 ± 21 to 86.1 ± 20.5 kg (P = 0.03), leg fat mass 17.8 ± 7.7 to 17.4 ± 7.6 kg (P = 0.008), total leg volume 12.9 ± 4 to 12 ± 3.5 L (P = 0.007), six of 20 calliper sites and tissue oedema. Pain scores did not change significantly. By ultrasound, six women had 22 hyperechoic masses in leg fat that resolved after treatment; five women developed seven new masses. Fascia improved by ultrasound after treatment. SAT therapy reduced amount and structure of fat in women with lipoedema and Dercum disease; studies are needed to compare SAT therapy to other therapies.
Subject(s)
Absorptiometry, Photon , Adiposis Dolorosa/therapy , Body Composition , Lipedema/therapy , Ultrasonography , Adiposis Dolorosa/diagnostic imaging , Adiposis Dolorosa/physiopathology , Adult , Body Weight , Female , Humans , Lipedema/diagnostic imaging , Lipedema/physiopathology , Middle Aged , Pain , Prospective Studies , Subcutaneous Fat/diagnostic imagingABSTRACT
The lon(-) mutants of Escherichia coli grow apparently normally except that, after temporary periods of inhibition of deoxyribonucleic acid synthesis, septum formation is specifically inhibited. Under these conditions, long, multinucleate, nonseptate filaments result. The lon(-) mutation also creates a defect such that wild-type bacteriophage lambda fails to lysogenize lon(-) mutants efficiently and consequently forms clear plaques on a lon(-) host. Two lines of evidence suggest that this failure probably results from interference with expression of the lambdacI gene, which codes for repressor, or with repressor action:-(i) when a lon(-) mutant was infected with a lambdacII, cIII, or c Y mutant, there was an additive effect between the lon(-) mutation and the lambdac mutations upon reduction of lysogenization frequency; and (ii) lon(-) mutants permitted the growth of the lambdacro(-) mutant under conditions in which the repressor was active. The isolation of lambda mutants (lambdatp) which gained the ability to form turbid plaques on lon(-) cells is also reported.